Recursion Pharmaceuticals, Inc. (RXRX): Capital Expenditures
$6.47M
Year ended 2025-12-31
$1.79M
Trailing 12 months to 2026-06-30
-44.1%
3-year compound annual growth
+2.1%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $6.47M | -52.8% | 2026-02-25, From 2025-01-01 |
| 2024-12-31 | $13.70M | +14.6% | 2026-02-25, From 2024-01-01 |
| 2023-12-31 | $11.96M | -67.7% | 2026-02-25, From 2023-01-01 |
| 2022-12-31 | $37.06M | -6.9% | 2025-02-28, From 2022-01-01 |
| 2021-12-31 | $39.80M | +582.5% | 2024-02-29, From 2021-01-01 |
| 2020-12-31 | $5.83M | +49.1% | 2023-02-27, From 2020-01-01 |
| 2019-12-31 | $3.91M | n/a | 2022-03-23, From 2019-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Recursion Pharmaceuticals, Inc. (RXRX) | 2025-12-31 | $6.47M | -52.8% |
| Autolus Therapeutics plc (AUTL) | 2025-12-31 | $19.04M | -13.7% |
| Compugen Ltd (CGEN) | 2025-12-31 | $306.0K | +159.3% |
| Black Diamond Therapeutics, Inc. (BDTX) | 2024-12-31 | $0 | -100.0% |
| Vir Biotechnology, Inc. (VIR) | 2025-12-31 | $4.83M | -33.8% |
| MeiraGTx Holdings plc (MGTX) | 2025-12-31 | $3.83M | -22.8% |
| 4D Molecular Therapeutics, Inc. (FDMT) | 2025-12-31 | $536.0K | -85.8% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $564.0K | +45.0% |
| Invivyd, Inc. (IVVD) | 2025-12-31 | $155.0K | +10.7% |
Compare RXRX, AUTL, CGEN, BDTX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗